KBLI 21014 is not on the closed, conditional, SME-reserved, or partnership schedules of Pres. Reg. 10/2021. That clears the ownership layer — PT PMA is structurally available. Sector regulators may still add overlays (see layer 02 below).
OSS issues the NIB and operating licence on the standard ladder, but BPOM / Kemenkes sets a higher capital floor or additional requirements under PMK 26/2018. Plan separate sector-regulator review timelines on top of OSS.
OSS lists 7 operational obligations at Large scale for this code. None are structural foreign-investor barriers, but they determine ongoing compliance: proof of submission of mandatory validated Industrial Data every 6 (six)…, Ensure the safety and security of equipment, processes, production results,…, and others.
Worth confirming: Openness here is based on BUPM (Pres. Reg. 10/2021). Sector regulators (PSE/Kominfo for digital platforms, BPOM for food and cosmetics, OJK for financial, Kemenkes for healthcare, Permendag for retail, ESDM for energy) often add licensing and capital requirements on top — the practical answer depends on your business model. Talk to our team
kbli2025VersionBanner.legacy2020Body 21014 (Pharmaceutical Raw Materials Industry for Animals). OSS adopts KBLI 2025 for new filings from 16 June 2026; existing entities continue under their 2020 code.
Pharmaceutical Ingredients for Animals
Last updated · Sourced from OSS Indonesia
This group includes the manufacturing and processing of medicinal materials, auxiliary materials, and packaging materials for animals, derived from chemicals, natural materials, animals, and plants, including those from biological sources, such as pharmaceuticals, antisera, and other blood fractions, vaccines, and homeopathic preparations. It also includes the industry of active pharmaceutical ingredients for pharmacological materials in the pharmaceutical industry, such as antibiotics, vitamins, salicylic acid, and o-acetylsalicylic acid, among others, blood processing, pure chemical sugar industry, gland processing industry, and gland extraction industry, among others.
Operating license routes through Ministry of Health (Kemenkes) / BPOM, not OSS — Emerhub handles the application end-to-end.
CPOB (Good Manufacturing Practice) certification mandatory for all production facilities.
BPOM Distribution Permit (NIE) required for each product SKU.
Foreign equity in branded pharmaceuticals open up to 100%; generic drugs may have local-partner requirements.
Indonesia's BUPM (Investment Business Fields) regulation places this code into one of five tracks. The track determines whether a foreign investor (PMA) can operate in this activity at all, and under what conditions.
KBLI 21014 is not on Indonesia's closed, conditional, SME-reserved, or partnership-required schedules under BUPM (Pres. Reg. 10/2021). A foreign investor can incorporate a PT PMA under this code, but sector regulators (PSE/Kominfo, BPOM, OJK, Kemenkes, Permendag, ESDM) almost always add licensing and capital requirements on top — the practical answer depends on your specific business model.
Foreign-investor tax benefits available for this KBLI under PMK 130/2020 (Tax Holiday) and PP 78/2019 (Tax Allowance). Both require approval — see the linked guide for the application path.
Note. Pharmaceutical manufacturing (KBLI 21xxx) is on the PP 78/2019 Tax Allowance priority list.
Pharmaceutical manufacturing (CPOB facilities)
Note. CPOB certification is the binding gate, not a flat capital number — meaningful capex needed for clean-room facility build.
BKPM Reg. 5/2025's default is IDR 2.5 billion paid-up + IDR 10 billion commitment per KBLI. The figure above is the binding override for this activity — the higher number wins.
Current status, what each regulation actually requires for this activity, and how it ties to the PB UMKU sector permits below. Click through for the plain-English summary.
Emerhub is a corporate-services provider in Indonesia. We do the legal and regulatory legwork for foreign investors so you can focus on the business itself. Here's what the engagement looks like.
We confirm KBLI 21014 is the right primary code for your business, advise on secondary codes you may also need, and finalize the holding structure with you before any filing.
We draft the Articles of Association before a notary, register the entity with the Ministry of Law & Human Rights (Kemenkumham), and obtain the company's tax ID (NPWP). Under BKPM Reg. 5/2025, paid-up capital is IDR 2.5 billion (~USD 160K) — the cash actually deposited at incorporation. The IDR 10 billion+ figure many sources still cite is the total investment commitment per KBLI, realised over time via your LKPM reports.
Specific permits, application requirements and ongoing obligations vary by business scale and the sub-activity within this KBLI. We file these on your behalf — this section is for transparency on what we'll be handling. Switch between scales below; by default we show Large (the PMA scale).
Documents and capabilities you must demonstrate at registration
Compliance and reporting duties throughout operation
The authority that issues the license depends on your situation.
| Authority | Applies when |
|---|---|
| Minister/Head of Agency | All of them |
| Minister/Head of Agency | Foreign Investment |
These are CANDIDATE permits the OSS dataset attaches to this KBLI. Each one only becomes mandatory when your operation actually performs the activity it governs (e.g. distributing pharmaceuticals, handling food, operating radiology equipment). Many businesses operating under this code need none of them; some need a handful. This KBLI carries 2 candidate permits across 1 regulator. Emerhub maps your actual operating scope to the exact subset, files them, and tracks renewals.
Conditional list.Each sector card below names the operational trigger. If your business does not perform that activity, that sector’s permits do not apply to you.
Ministry of Agriculture.
Required only ifApplies if you produce, import, distribute, or sell animal medicines, vaccines, or feed; if you breed livestock; or if you operate a veterinary practice. A "veterinary control number" (NKV) is the entry-point permit for animal-product processors.

We file the OSS application with KBLI 21014 as your primary business activity, complete the risk-based assessment, and collect the NIB (Business Identification Number) for you — typically within hours of submission. You don't need to touch the OSS portal.
NIB is issued for the preparation stage. To begin commercial operations, the operator must obtain a Sertifikat Standar that has been verified by the competent ministry. The verification step typically requires a site or document inspection. Operating with NIB alone is not legally compliant. We prepare the application bundle, liaise with the competent ministry, and chase issuance through to the certificate. Statutory turnaround: 7 business days — real-world timing typically runs longer when site inspections or additional clarifications are requested.
Post-launch we run your monthly tax filings, quarterly LKPM (Investment Activity Reports), annual general meeting (RUPS), and any sector-specific reporting. You get a single point of contact and a monthly compliance digest — no Indonesian-language paperwork on your desk.
› Pharmaceutical companies must comply with the governance and operational procedures outlined in this regulation.
› This code is relevant as it covers traditional medicines that must adhere to halal production standards.
› This code includes businesses involved in the distribution of vaccines, which are affected by the revocation of customs and tax facilities.
› Distributors of narcotics are required to follow the new regulations for monitoring and control.
› This code is relevant as it involves the production of narcotics and psychotropics, which are specifically regulated under this law.
A plain-English explanation of this classification and the businesses it covers.
KBLI 21014 (Pharmaceutical Ingredients for Animals) is the 5-digit Indonesian Standard Industrial Classification code for pharmaceutical industry for animals. It sits within Manufacturing Industry under the subgroup Pharmaceutical and Chemical Medicinal Product Industry (major group 21) in the official KBLI 2020 taxonomy maintained by Statistics Indonesia (BPS).
Any Indonesian or foreign-owned entity that intends to operate in pharmaceutical industry for animals as a primary or secondary business activity must select this code on its NIB (Business Identification Number). The selected code determines the licensing instruments required, the issuing authority, and the ongoing compliance obligations.
Indonesia's OSS Risk-Based Approach uses the KBLI code to determine three things: (1) whether foreign investment is permitted and at what cap, (2) the risk-based licensing instruments required, and (3) the authority that issues each instrument. Choosing the wrong code can delay or invalidate your license.
Indonesia's BPS published the KBLI 2025 taxonomy in 2025 and OSS adopts it for new business registrations from 16 June 2026. KBLI 2020 codes already on file remain valid for the entities they were issued to; new filings select 2025 codes. This is what changes for this specific code.
KBLI 21014 retains the same code number and scope in the new taxonomy. The activity description, hierarchy, and intended use of the code are preserved.
For new filings from 16 June 2026, Emerhub selects the right KBLI 2025 code, handles the OSS submission, and migrates existing entities to a successor code only when the registered scope requires it.
Talk to a specialistIndonesia's OSS Risk-Based Approach assigns a separate risk level for each of the four business scales. The licensing instruments required (NIB, Standard Certificate, Operating License) are determined by the risk level. Foreign-owned entities (PT PMA) must register at the Large scale, so the rightmost column applies to most foreign investors.
KBLI 21014 (Pharmaceutical Ingredients for Animals) is the 5-digit Indonesian Standard Industrial Classification code for pharmaceutical industry for animals. It sits within the Manufacturing Industry category in the official KBLI 2020 taxonomy maintained by Badan Pusat Statistik (BPS).
KBLI 21014 is open to PT PMA under BUPM (Pres. Reg. 10/2021) — it is not on the closed, conditional, SME-reserved, or partnership-required schedules. That is the BUPM verdict only: sector regulators (PSE/Kominfo for digital platforms, BPOM for food and cosmetics, OJK for financial, Kemenkes for healthcare, Permendag for retail, ESDM for energy) commonly add licensing and capital requirements on top depending on the specific business model. Confirm the practical setup with our team before committing capital.
KBLI 21014's risk levels per business scale: Micro Medium-High, Small Medium-High, Medium Medium-High, Large Medium-High. Foreign-owned entities (PT PMA) must register at the Large scale.
NIB + verified Standard Certificate (Sertifikat Standar Terverifikasi). KBLI 21014 is Medium-High risk at Large scale, so NIB is issued first, but the Standard Certificate becomes effective only after the issuing ministry verifies compliance (typically through a document review or site audit). To obtain the licensing instrument, OSS lists 5 application requirements (persyaratan). The first few: Have a document outlining the plan for the type, specifications, quantity, and source of raw materials, as…; Possess documents in the form of: a. Machine specifications and/or equipment list b. Photos of…; Have a human resources organizational structure document that includes at least: a. Company leadership b.…, and 2 more — see the full list with supporting documents in the Licensing detail section. 2 sector-specific PB UMKU permits also apply depending on the exact activity. See the requirements summary at the top of the page.
Sector regulator override: No fixed minimum, but GMP-compliant facility build typically IDR 50-100 billion+ required by BPOM / Kemenkes under PMK 26/2018 (Pelayanan Perizinan Berusaha Terintegrasi Sektor Kesehatan). This is higher than BKPM Reg. 5/2025's default IDR 2.5 billion paid-up; the higher number wins. See the investment status block for the ownership context.
PT PMA setup typically takes 4-8 weeks: AHU registration (1-2 weeks), NIB issuance via OSS (immediate to 1 week), bank account opening (2-4 weeks). The licensing cycle for KBLI 21014 specifically takes 7 days at the Large business scale.
Yes — KBLI 21014 is on the Tax Allowance priority list (PP 78/2019). Eligible for 30% reduction of taxable net income over 6 years plus accelerated depreciation.
Authority depends on the investor profile. For PMA: Minister/Head of Agency. For domestic SME scale: typically Governor (for Provincial scope) or Regent/Mayor (Regency/City scope). See the licensing detail section for the full per-permit authority routing.
Beyond the NIB, KBLI 21014 carries 2 PB UMKU permits across 1 sector regulator: Veterinary & Animal Medicine (2). Most operations only need 2-4 of these. The relevant set depends on which specific activities you actually perform; Emerhub maps the right subset before filing. See the full PB UMKU list for per-permit detail and regulator routing.
KBLIs in the same subgroup 2101: 21011 (Pharmaceutical Materials Industry for Humans); 21012 (Pharmaceutical Products Industry for Humans); 21013 (Animal Pharmaceutical Industry); 21015 (Medical Devices Industry in Subgroup 2101). These are closely related activities — see the related-codes section below for full list.